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Neighbourhood Watch in Early Skin Cancer
An emerging view in cancer biology is that the tumor cell micro-
environment plays a role in the modulation of neoplastic progression
and phenotype. In stratified squamous epithelium, normal cells have
the capacity to suppress the early stages of neoplasia in neighbouring
cells with malignant potential. Modification of these normal cells by
ultraviolet radiation or 12-O-tetradecanoylphorbol-13-acetate (TPA)
can abrogate this growth-suppression. Many tumours (including skin
tumours) are thought to arise as a result of multiple somatic genetic
events that generate a premalignant lesion consisting of cells at varying
stages of cancer progression. On page 384, Vaccariello et al address
whether neighboring cells at an early stage of the transformation process
are potentially important in skin tumorigenesis by permitting clonal
expansion of cells at a more advanced stage of transformation (perhaps
simply by acting as a buffering zone between normal keratinocytes and
the more malignant cells).
Using an organotypic model of early neoplasia, in which β-
galactosidase-transduced malignant keratinocytes were mixed in three
dimensional cultures with normal human keratinocytes or with immor-
talized HaCaT cells, the authors show that HaCaT cells allowed clonal
expansion of malignant keratinocytes, whereas normal keratinocytes
Limitations in Predicting Phenotype in Hereditary Blistering Disorders from Mutation
Analysis of Genomic DNA
Molecular analysis of various types of epidermolysis bullosa (EB) has
allowed some genotype-phenotype correlations to be made, but as
more evidence accumulates it is becoming clear that the molecular
pathogenesis underlying these disorders is more complex. For example,
mutations in different regions of the keratin 5 or 14 genes were initially
thought to account for different clinical subtypes of EB simplex (EBS),
and mutations in those areas encoding the ends of the central rod
domain, and the helix initiation or termination sites were associated
with more severe disease. However, it is now known that each of the
three major types of EBS can result from missense mutations at a single
identical site.
Similarly, in the more severe forms of recessive dystrophic EB
(RDEB) and junctional EB (JEB), both copies of the type VII collagen
(COL7 A1) gene or laminin 5 genes (LAMA3, LAMB3, and LAMC2),
respectively, have usually contained nonsense or frameshift mutations.
Now, McGrath et al (p. 314) report on two unrelated families, one
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were not permissive for expansion. Furthermore, in contrast to normal
keratinocytes, which induced filaggrin expression in the malignant
keratinocytes, surrounding HaCaT cells were unable to induce differen-
tiation in the malignant keratinocytes. The mechanism for this growth
suppression seems to arise from direct cell contact rather than soluble
factors secreted by the normal keratinocytes, because malignant supraba-
sal cells that were growth-suppressed by normal keratinoctyes in normal
tissue context were again able to clonally expand in submerged cultures
when trypsinised from organotypic cultures and grown in the presence
of normal keratinocytes that were not in direct contact with the
malignant cells. The use of HaCaT cells (which contain p53 mutations)
in the study would seem to be all the more relevant because other
workers have shown that human skin chronically exposed to ultraviolet
radiation contains multiple clones of p53 mutated cells, in which it is
hypothesised that skin cancers later arise.
Disruption of normal tissue architecture by the immortalized
HaCaT cells can therefore abrogate the ‘‘neighbourhood watch
system’’ employed by normal keratinocytes to control clonal
expansion of potentially malignant cells in skin and may perhaps
permit the progression of clones of dysplastic, premalignant cells to
full blown cancer.
with RDEB and one with JEB in which affected individuals exhibit a
milder phenotype but contain frameshift and/or nonsense mutations
in both alleles of the respective genes. Surprisingly in the RDEB
family, although the genomic DNA sequences would have predicted
severely truncated type VII collagen, cDNA analysis revealed in-frame
skipping of the exon containing the frameshift mutation, resulting in
a mildly truncated protein and anchoring fibrils whose function is
sufficient to limit the severity of the blistering. In the JEB family, the
combination of frameshift/nonsense mutations in LAMB3 resulted in
an in-frame deletion of exon 17 in the cDNA from the nonsense
allele, and although immunostaining with a β3 chain antibody was
completely negative, weak immunopositivity was seen for both the γ2
and α3 chains, consistent with the milder than expected phenotype.
The message emerging from studies such as this is that genotype-
phenotype correlations in EB cannot be reliably made on simple
sequencing of genomic DNA, but that a combination of techniques
is required.
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PUVA: The Long Burn?
Ever since Barry Marshall’s discovery of Helicobacter as the cause of
peptic ulceration, there seems ever less reason to doubt the maxim
that potential major clinical discoveries lie all around us; so often it
seems what is required is not only an ability to challenge (or ignore)
conventional wisdom but an ability to model the right clinical question
experimentally. Peter Farr and Sally Ibbotson on p. 346 offer us one
such modest, but important, example.
First a little background. The clinical use of PUVA has been largely
empiric with major differences in dosage regimes between different
centres. One issue has related to how often the therapy is administered,
twice, three or even four times a week. How should we chose? Firstly,
and obviously, on the basis of efficacy. But one key trade off that we
have to factor in early, relates to side-effects, most notably and obviously
burning. How do we take this on board in designing therapeutic
regimens? Farr and Ibbotson point out that the kinetics of erythema
are critical. If PUVA erythema peaks after say 3 d, dosage regimens
more frequent than this may run the risk of cumulative erythema,
which might translate as more burning, which in turn will influence
compliance. In a straightforward piece of clinical science they show
that contrary to previous dogma or ex cathredra statements PUVA
erythema peaks at 96 h. A simple conclusion is that phototesting to
determine dosage regimens should take this into account. What
however, about the frequency of PUVA therapy: should this be reduced
to every 96 h? Farr and Ibbotson are rightly more cautious here. The
answer is as yet not clear-cut and requires further experimentation.
The pattern of accumulation of erythema will be heavily dependent
on the order of kinetics of removal of erythema following multiple
exposures, in particular, any interaction between degree of erythema
and speed of removal. Single dose kinetics may provide a model for
this or they may not. Second, what is limiting in clinical terms is pain
or discomfort rather than erythema. Whether the relation between
pain and erythema is constant or context dependent also will require
further investigation. There is one other thought for the future: dosage
regimens may not only influence immediate toxicity, in terms of
burning, but it also becomes ever less fanciful to imagine that these
acute inflammatory profiles may influence carcinogenicity. For the
present we should note – yet again – that the textbooks are wrong.
